ADHD Mortality Risk: Meta-Analysis and USMLE Review

A systematic review and meta-analysis in JAMA Network Open pooled 19 observational studies covering close to 16 million people on three continents. It found that ADHD was associated with a higher rate of death from any cause, including suicide, injuries, and natural causes. Among people with ADHD, those taking medication appeared to have lower mortality, but that finding rested on only three studies, and no causal conclusions can be drawn.

What happened

Lucy Corrigan and colleagues (University of Liverpool and UCL) reviewed 19 studies that followed large groups of people with and without an ADHD diagnosis for multiple years. Some followed participants for more than 20 years. The goal was to compare mortality between the groups.

The reported results for people with an ADHD diagnosis, compared with people without one:

• All-cause mortality: 70% higher rate of death.
• Suicide: 90% higher rate.
• Injury deaths (intentional or accidental): 55% higher rate.
• Natural-cause deaths: 27% higher rate.

Among people with ADHD, those who took ADHD medication appeared to have a 25% lower mortality risk. The authors stress that this estimate came from only three of the 19 studies.

Why it matters

The senior author, Joshua Stott, noted that the group had previously found reduced life expectancy in people with ADHD. This analysis looks at what may be driving that. The excess risk was not limited to suicide and injuries. Natural-cause mortality was also moderately higher, which the authors read as evidence that the health inequalities faced by people with ADHD are broad.

The authors suggest several possible explanations:

• More mental health problems, difficulty with emotional regulation, impulse control, and risk-taking.
• Societal exclusion, disadvantage, and stigma.
• Differences in attention that may contribute to unintentional injury deaths, such as road deaths.
• Health risk behaviors such as smoking or alcohol use, which may contribute to natural-cause mortality.
• Difficulties with engagement and access to health care, and with adherence to treatment.

The same group's earlier work found higher rates of cardiovascular disease, metabolic disorders, diabetes, and cancer in people with ADHD. The authors also argue that ADHD is not by definition life-limiting, and that diagnosis rates may still lag behind true prevalence, particularly in older adults.

What to know for the USMLE: ADHD high-yield review

The study is not a test topic itself, but it connects to a very testable area. Here is what Step 1 and Step 2 CK expect.

• Diagnosis (DSM-5): Several symptoms of inattention and/or hyperactivity-impulsivity must be present before age 12. They must appear in two or more settings (home, school, work) and clearly impair function. Symptoms must last at least 6 months. ADHD is a clinical diagnosis, and it must not be better explained by another disorder.
• Neurobiology: Dysregulation of dopamine and norepinephrine signaling, particularly in prefrontal circuits involved in executive function, is the classic model.
• First-line drugs: stimulants. Methylphenidate blocks dopamine and norepinephrine reuptake. Amphetamine salts also increase presynaptic release of catecholamines. Both are Schedule II drugs with misuse potential.
• Stimulant adverse effects: decreased appetite and weight loss, insomnia, tachycardia, increased blood pressure, and tics or anxiety in some patients. Slowed growth is a classic pediatric concern. Rare psychosis is also tested.
• Nonstimulants: Atomoxetine is a selective norepinephrine reuptake inhibitor and is not a controlled substance. It carries a boxed warning for suicidal ideation in children and adolescents. Guanfacine and clonidine are alpha-2 agonists, often used as extended-release adjuncts or alternatives, and can cause sedation and hypotension. Viloxazine is another nonstimulant option.
• When nonstimulants come up: Exam stems often involve comorbid tics, substance use disorder, or stimulant intolerance.
• Comorbidity: Expect oppositional defiant disorder, conduct disorder, anxiety, depression, learning disorders, tic disorders, and substance use disorder. Always screen for these. Mood disorders and substance use also matter for the suicide and injury risk discussed above.
• Management by age: In preschool-aged children, behavioral interventions come first. In school-aged children, medication combined with behavioral therapy is standard. ADHD often persists into adulthood.
• Biostatistics tie-in: A meta-analysis pools results across studies. Expect questions on heterogeneity (I²), forest plots, publication bias (funnel plot), and the fact that pooling observational studies does not remove confounding. This study is a clean example for those concepts.

Limitations

The authors themselves point out several important caveats.

• Observational design. All 19 studies were observational, so causality cannot be inferred. ADHD may be a marker of other risks rather than the cause of the extra deaths.
• Large heterogeneity. The studies generally found higher mortality in ADHD, but the size of the effect differed widely between them. A single pooled figure should be read with that in mind.
• Medication finding is preliminary. The 25% lower mortality in medicated people came from only three studies. Corrigan described it as "early evidence" that needs further research. In general, observational medication comparisons can be affected by who gets treated and who stays on treatment, which is why such results need cautious reading.
• Diagnosed ADHD only. The comparisons are between people with and without a diagnosis. Undiagnosed ADHD would not be captured, and the authors note that diagnosis may still lag behind true prevalence.
• Relative, not absolute, risk. The figures reported are relative increases. This article's source material does not give absolute event rates, so the real-world size of the risk cannot be judged from the percentages alone.

This article is educational and not a source of treatment advice for any individual.

FAQ

Does ADHD cause early death, according to this study?

No. The studies were observational, so they show an association, not causation. The authors emphasize that ADHD is not by definition life-limiting and that the right support and treatment can help people live long, healthy lives.

Does ADHD medication reduce mortality?

Possibly, but this is not established. People with ADHD who took medication appeared to have a 25% lower mortality risk. However, the estimate came from only three of the 19 studies, and the authors call for more research.

What causes of death were higher in ADHD?

The pooled data showed higher rates of death from suicide (90% higher), injuries (55% higher), and natural causes (27% higher). The overall all-cause rate was 70% higher than in people without an ADHD diagnosis.

Key takeaways

• A meta-analysis of 19 observational studies (~16 million people) linked ADHD to a 70% higher all-cause mortality rate, with higher suicide, injury, and natural-cause deaths.
• Medication use was associated with 25% lower mortality, but this rests on only three studies. Results varied substantially between studies, and causality cannot be inferred.
• For the USMLE, review ADHD diagnostic criteria, stimulants vs nonstimulants (mechanisms and adverse effects), common comorbidities, and how to critique a meta-analysis of observational data.